Neurocrine (1NBIX) Stock Price & Analysis
1NBIX Stock Chart & Stats
- Day’s Range
- EUR 131.25 - EUR 131.85
- 52-Week Range
- EUR 58.00 - EUR 231.00
- Previous Close
- EUR 130.50
- Volume
- 21
- Average Volume (3M)
- 12
- Market Cap
- EUR 13.25B
- Enterprise Value
- EUR 17.57B
- Total Cash (Recent Filing)
- EUR 389.80M
- Total Debt (Recent Filing)
- EUR 401.80M
- Price to Earnings (P/E)
- 20.7
- Beta
- 0.36
- Next Earnings
- Nov 02, 2026 (Est.)
- EPS Estimate
- 1.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High-margin Profitability
Neurocrine combines sustained revenue expansion with exceptionally high gross profitability and improving net and operating margins. This creates substantial earnings leverage, supports ongoing investment in commercial and pipeline programs, and provides a durable foundation for cash generation.
Commercial Product Momentum
The marketed portfolio is demonstrating durable adoption across established and newer products. INGREZZA growth, CRENESSITY penetration, strong persistency, and favorable reimbursement broaden the company’s revenue base and support continued commercial scaling.
Strong Cash Generation
Cash generation closely tracks reported earnings, indicating strong earnings quality rather than growth dependent primarily on accounting gains. Robust free cash flow gives Neurocrine resources to fund research, commercialization, partnerships, and strategic investments from internal operations.
Bears Say
Decelerating Growth
Although revenue remains positive, the marked slowdown from earlier expansion raises the importance of successful product launches and pipeline execution. Lower underlying growth can reduce operating leverage over time and make future earnings increasingly dependent on a smaller number of key programs.
Acquisition Liquidity And GAAP Pressure
The Soleno transaction adds strategic scale but materially reduced liquidity and introduces substantial integration, transaction, amortization, and purchase-accounting costs. These effects can constrain financial flexibility and weigh on GAAP earnings while management works to realize the deal’s benefits.
VYKAT XR Launch Execution Risk
VYKAT XR provides meaningful acquired revenue, but early discontinuations and a flat sequential sales trend make its contribution less predictable during the integration period. Continued execution will be needed to improve retention, optimize the sales force, and establish durable growth.
Neurocrine News
1NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
What is Neurocrine’s market cap?
When is Neurocrine’s upcoming earnings report date?
How were Neurocrine’s earnings last quarter?
Is Neurocrine overvalued?
Does Neurocrine pay dividends?
What is Neurocrine’s EPS estimate?
How many shares outstanding does Neurocrine have?
What happened to Neurocrine’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Neurocrine?
What is the TipRanks Smart Score and how is it calculated?
Neurocrine Stock Smart Score
Company Description
Neurocrine
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kyle W. Gano
- Employees
- 2,500
- Website
- www.neurocrine.com
- Address
- 6027 Edgewood Bend Court, San Diego, CA, 92130, US
Neurocrine (1NBIX) Earnings & Revenues
1NBIX Company Deck
1NBIX Earnings Call
Earnings Call SentimentPositive
The call conveyed strong commercial execution and significant growth: near-record quarterly sales, raised INGREZZA guidance, sustained CRENESSITY launch momentum, immediate accretion from the VYKAT XR acquisition, and a deep pipeline with material Phase 3 catalysts in 2027. Key negatives are near-term GAAP headwinds and cash use from the ~$2.9B acquisition, early-stage launch variability and discontinuations for VYKAT XR, and lingering policy/pipeline outcome uncertainties that could create EPS variability. Overall, the positive operational and pipeline developments outweigh the transitional and financial integration challenges.
View all IT:1NBIX earnings summaries1NBIX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 11 | 0 | 1 |